Perspective Therapeutics updates pipeline: VMT-α-NET durable disease control; VMT01 and PSV359 progress

Perspective Therapeutics, Inc.

VMT-α-NET (SSTR2+ NET) Phase 1/2a shows durable disease control; potential registration study at current dose level.
VMT01 (MC1R melanoma) Phase 1/2a: preliminary anti-tumor activity observed at 3.0 mCi dose.
PSV359 (FAP-ɑ solid tumors) Phase 1/2a demonstrates improved tumor retention in ongoing trial.
Integrated isotope production enables direct-to-hospital delivery and regional manufacturing for supply.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.